These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25350931)

  • 1. Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors.
    Rudolph J; Xiao Y; Pardi A; Ahn NG
    Biochemistry; 2015 Jan; 54(1):22-31. PubMed ID: 25350931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure.
    Chen F; Hancock CN; Macias AT; Joh J; Still K; Zhong S; MacKerell AD; Shapiro P
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6281-7. PubMed ID: 17000106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2.
    Pegram LM; Liddle JC; Xiao Y; Hoh M; Rudolph J; Iverson DB; Vigers GP; Smith D; Zhang H; Wang W; Moffat JG; Ahn NG
    Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15463-15468. PubMed ID: 31311868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site.
    Callaway K; Abramczyk O; Martin L; Dalby KN
    Biochemistry; 2007 Aug; 46(32):9187-98. PubMed ID: 17658892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
    Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
    Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of human mono-phosphorylated ERK1 at Tyr204.
    Kinoshita T; Yoshida I; Nakae S; Okita K; Gouda M; Matsubara M; Yokota K; Ishiguro H; Tada T
    Biochem Biophys Res Commun; 2008 Dec; 377(4):1123-7. PubMed ID: 18983981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERK1/2 MAP kinases: structure, function, and regulation.
    Roskoski R
    Pharmacol Res; 2012 Aug; 66(2):105-43. PubMed ID: 22569528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2).
    Li L; Liu F; Jin N; Tang S; Chen Z; Yang X; Ding J; Geng M; Jiang L; Huang M; Cao J
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2600-4. PubMed ID: 27106711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel extracellular signal-regulated kinase docking domain inhibitors.
    Hancock CN; Macias A; Lee EK; Yu SY; Mackerell AD; Shapiro P
    J Med Chem; 2005 Jul; 48(14):4586-95. PubMed ID: 15999996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The WW domain of the scaffolding protein IQGAP1 is neither necessary nor sufficient for binding to the MAPKs ERK1 and ERK2.
    Bardwell AJ; Lagunes L; Zebarjedi R; Bardwell L
    J Biol Chem; 2017 May; 292(21):8750-8761. PubMed ID: 28396345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics.
    Chaikuad A; Tacconi EM; Zimmer J; Liang Y; Gray NS; Tarsounas M; Knapp S
    Nat Chem Biol; 2014 Oct; 10(10):853-60. PubMed ID: 25195011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residence time and kinetic efficiency analysis of extracellular signal-regulated kinase 2 inhibitors.
    Vanderpool D; Grimshaw CE; Lawson JD; Ermolieff J
    Anal Biochem; 2015 Mar; 473():46-52. PubMed ID: 25535956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.
    Sammons RM; Perry NA; Li Y; Cho EJ; Piserchio A; Zamora-Olivares DP; Ghose R; Kaoud TS; Debevec G; Bartholomeusz C; Gurevich VV; Iverson TM; Giulianotti M; Houghten RA; Dalby KN
    ACS Chem Biol; 2019 Jun; 14(6):1183-1194. PubMed ID: 31058487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity.
    Awadallah FM; Abou-Seri SM; Abdulla MM; Georgey HH
    Eur J Med Chem; 2015 Apr; 94():397-404. PubMed ID: 25778995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-gel activity-based protein profiling of a clickable covalent ERK1/2 inhibitor.
    Lebraud H; Wright DJ; East CE; Holding FP; O'Reilly M; Heightman TD
    Mol Biosyst; 2016 Aug; 12(9):2867-74. PubMed ID: 27385078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases.
    Miller CJ; Muftuoglu Y; Turk BE
    Biochem Pharmacol; 2017 Oct; 142():39-45. PubMed ID: 28647489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.
    Jasek-Gajda E; Jurkowska H; Jasińska M; Litwin JA; Lis GJ
    Apoptosis; 2019 Dec; 24(11-12):849-861. PubMed ID: 31482470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.
    Boga SB; Alhassan AB; Cooper AB; Doll R; Shih NY; Shipps G; Deng Y; Zhu H; Nan Y; Sun R; Zhu L; Desai J; Patel M; Muppalla K; Gao X; Wang J; Yao X; Kelly J; Gudipati S; Paliwal S; Tsui HC; Wang T; Sherborne B; Xiao L; Hruza A; Buevich A; Zhang LK; Hesk D; Samatar AA; Carr D; Long B; Black S; Dayananth P; Windsor W; Kirschmeier P; Bishop R
    Bioorg Med Chem Lett; 2018 Jun; 28(11):2029-2034. PubMed ID: 29748051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propofol post-conditioning protects against cardiomyocyte apoptosis in hypoxia/reoxygenation injury by suppressing nuclear factor-kappa B translocation via extracellular signal-regulated kinase mitogen-activated protein kinase pathway.
    Li H; Tan J; Zou Z; Huang CG; Shi XY
    Eur J Anaesthesiol; 2011 Jul; 28(7):525-34. PubMed ID: 21666544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.
    Ward RA; Colclough N; Challinor M; Debreczeni JE; Eckersley K; Fairley G; Feron L; Flemington V; Graham MA; Greenwood R; Hopcroft P; Howard TD; James M; Jones CD; Jones CR; Renshaw J; Roberts K; Snow L; Tonge M; Yeung K
    J Med Chem; 2015 Jun; 58(11):4790-801. PubMed ID: 25977981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.